Kava derived therapeutic compounds and methods of use thereof
US10918687B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 23, 2020 |
| Grant date | Feb 16, 2021 |
| Priority date | — |
| Expiry date | Jan 23, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2236/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.